chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: VARZOS
Symptoms: Thrombosis
Clinical narrative: got 2 blood clots in my left leg; This serious case was reported by a consumer via interactive digital media and described the occurrence of thrombosis leg in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced thrombosis leg (Verbatim: got 2 blood clots in my left leg) (serious criteria GSK medically significant).  The outcome of the thrombosis leg was not reported.   The reporter considered the thrombosis leg to be possibly related to Shingrix.     The company considered the thrombosis leg to be possibly related to Shingrix.   Additional Information: GSK Receipt date: 21-SEP-2023 This case was reported by patient via interactive digital media. The patient reported that after 1 Shingles shot, she got 2 blood clots in her left leg. Patient states that she had friends who had shingles. The pain they described sounded unbearable and she educated herself about the risks and what she could do for prevention. The reporter thought that the event might had been related to the drug. Follow up was not possible as no contact details were available.
Sex: M
Vaccine: VARZOS
Symptoms: Incorrect dose administered, Product preparation issue
Clinical narrative: Administration of the adjuvant only/No reconstitution; Administration of the adjuvant only/No reconstitution; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: Administration of the adjuvant only/No reconstitution) and inappropriate dose of vaccine administered (Verbatim: Administration of the adjuvant only/No reconstitution).The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 18-SEP-2023 The reporter called to ask for information regarding a patient who received only the adjuvant portion of Shingrix (no reconstitution), which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The healthcare professional asked how to proceed with this patient. The reporter did not provide information regarding patient (initials, age) nor information about the dose (lot number, expiry date, date of administration. The reporter did not consent to follow-up.
Age: 76.0
Sex: F
Vaccine: RSV
Symptoms: Arthralgia, Injection site erythema, Injection site pruritus, Injection site warmth
Clinical narrative: a 2.25 inch diameter reddened area of the injected (Right) arm; itch; reddened area was hot; achy joints; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 76-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 3AK2K, expiry date 09-DEC-2024) for prophylaxis.   The patient's past medical history included covid-19. Previously administered products included Covid vaccines (received covid vaccines on an unknown date ). Concurrent medical conditions included post-traumatic stress disorder (have had post-traumatic stress disorder (PTSD)).   On 05-SEP-2023, the patient received Arexvy (right arm). In SEP-2023, an unknown time after receiving Arexvy, the patient experienced injection site erythema (Verbatim: a 2.25 inch diameter reddened area of the injected (Right) arm), injection site itching (Verbatim: itch), injection site warmth (Verbatim: reddened area was hot) and joint pain (Verbatim: achy joints).  The outcome of the injection site erythema was not resolved and the outcome of the injection site itching, injection site warmth and joint pain were resolved.   It was unknown if the reporter considered the injection site erythema, injection site itching, injection site warmth and joint pain to be related to Arexvy.     It was unknown if the company considered the injection site erythema, injection site itching, injection site warmth and joint pain to be related to Arexvy.   Additional Information: GSK receipt date: 19-Sept-2023 The patient received Arexvy and ever since the patient experienced a 2.25 inch diameter reddened area of the injected arm. The patient stated that the reddened area was hot for along time and also itched a lot. At the time of call, the reddened area was still there but had faded. The patient also experienced achy joints. The patient reported that she had never reacted to any other vaccine. The reporter did not consent to follow-up.
Age: 34.0
Sex: F
Vaccine: HEP
Symptoms: Incorrect dose administered, Product administered to patient of inappropriate age
Clinical narrative: she administered a pediatric dose of Engerix-B to an adult today; she administered a pediatric dose of Engerix-B to an adult today; This non-serious case was reported by a other health professional via call center representative and described the occurrence of underdose in a 34-year-old female patient who received HBV (Engerix B pediatric) (batch number A9349, expiry date 19-APR-2024) for prophylaxis.   On 19-SEP-2023, the patient received the 3rd dose of Engerix B pediatric. On 19-SEP-2023, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: she administered a pediatric dose of Engerix-B to an adult today) and adult use of a child product (Verbatim: she administered a pediatric dose of Engerix-B to an adult today).  The outcome of the underdose and adult use of a child product were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 19-SEP-2023 CMA states that she administered a pediatric dose of Engerix-B to an adult on the reporting day, which led to underdose and adult use of a child product. The reporter consented to follow up via postal. The vaccine administration facility is the same as primary reporter.
Age: 3.0
Sex: M
Vaccine: HEPA
Symptoms: Incorrect dose administered, Product administered to patient of inappropriate age
Clinical narrative: patient received an adult dose of Havrix as a 2nd dose by mistake, patient is 3 years of age; patient received an adult dose of Havrix as a 2nd dose by mistake, patient is 3 years of age; This non-serious case was reported by a physician via call center representative and described the occurrence of accidental overdose in a 3-year-old male patient who received HAV (Havrix adult) (batch number 772YT, expiry date 23-SEP-2025) for prophylaxis.   On 20-SEP-2023, the patient received the 2nd dose of Havrix adult. On 20-SEP-2023, an unknown time after receiving Havrix adult, the patient experienced accidental overdose (Verbatim: patient received an adult dose of Havrix as a 2nd dose by mistake, patient is 3 years of age) and adult product administered to child (Verbatim: patient received an adult dose of Havrix as a 2nd dose by mistake, patient is 3 years of age).  The outcome of the accidental overdose and adult product administered to child were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 20-SEP-2023 The reporter was a pediatrician. The patient received an adult dose of Havrix as a 2nd dose by mistake, patient was 3 years of age, which led to accidental overdose and adult product administered to child. The reporter asked how to proceed. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up.
Sex: F
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: Shingrix never got the second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix  (1st dose received on 2020 from lot number 7AS54 and expiry date 15th May 2022).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: Shingrix never got the second dose). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 21-SEP-2023 The reporter asked if the patient needs to restart the series. Till the time of reporting, the patient did not receive the 2nd dose, which led to incomplete course of vaccination. The reporter consented to follow up.
Sex: M
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: Second dose had not been administered yet; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 84-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received around 5 years before date of reporting).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: Second dose had not been administered yet). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 21-SEP-2023 Till the time of reporting, the patient did not receive the 2nd dose, which led to incomplete course of vaccination. The reporter did not consent to follow up.
Age: 76.0
Sex: F
Vaccine: UNK
Symptoms: Extra dose administered, No adverse event
Clinical narrative: No adverse event; He got distracted and gave the patient two doses of the Moderna vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXTRA DOSE ADMINISTERED (He got distracted and gave the patient two doses of the Moderna vaccine) and NO ADVERSE EVENT (No adverse event) in a 76-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch nos. 3030371 and 3030371) for COVID-19 prophylaxis.     Previously administered products included for COVID-19 prophylaxis: Moderna covid-19 vaccine (lot number 019H22A) on 01-May-2023. Past adverse reactions to the above products included No adverse event with Moderna covid-19 vaccine. Concurrent medical conditions included Respiratory disorder.   On 18-Sep-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) .5 milliliter. On 18-Sep-2023, received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) dosage was changed to .5 milliliter. On 18-Sep-2023,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024), the patient experienced EXTRA DOSE ADMINISTERED (He got distracted and gave the patient two doses of the Moderna vaccine). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXTRA DOSE ADMINISTERED (He got distracted and gave the patient two doses of the Moderna vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXTRA DOSE ADMINISTERED (He got distracted and gave the patient two doses of the Moderna vaccine).    No concomitant medication was reported.  No treatment information was reported.
Age: 60.0
Sex: F
Vaccine: UNK
Symptoms: Injection site discharge, No adverse event, Product administration error
Clinical narrative: No adverse event; The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.; The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.; This spontaneous case was reported by a patient and describes the occurrence of PRODUCT LEAKAGE (The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.), PRODUCT ADMINISTRATION ERROR (The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.) and NO ADVERSE EVENT (No adverse event) in a 60-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     Patient had no known allergy, medications and health conditions.     On 25-Sep-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On 25-Sep-2023, the patient experienced PRODUCT LEAKAGE (The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.) and PRODUCT ADMINISTRATION ERROR (The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT LEAKAGE (The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.), PRODUCT ADMINISTRATION ERROR (The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT LEAKAGE (The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.) and PRODUCT ADMINISTRATION ERROR (The vaccine leaked in her arm when they pull out the needle of the vaccine after injecting.).    Concomitant medication was not provided. Patient got the Moderna shot, and the vaccine was leaked in her arm when they pulled out the needle of the vaccine after injecting. Patient was concerned because it never happened before. Patient mentioned that the Pharmacist was aware and saw what happened and Pharmacist answered it as " it is no big deal". Treatment information was not reported.
Age: 39.0
Sex: M
Vaccine: UNK
Symptoms: Feeling abnormal, Pain in extremity
Clinical narrative: Feeling generally bad; Arm hurting; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (Feeling generally bad) and PAIN IN EXTREMITY (Arm hurting) in a 39-year-old male patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    On 25-Sep-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (Feeling generally bad) and PAIN IN EXTREMITY (Arm hurting). At the time of the report, FEELING ABNORMAL (Feeling generally bad) and PAIN IN EXTREMITY (Arm hurting) outcome was unknown.            Concomitant medication was not provided. Treatment information was not reported.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Asthenia, COVID-19, Cardiac arrest, Computerised tomogram head normal
Clinical narrative: presented to ER with weakness, increase confusion, hallucinations and decreased mobility. Patient has hx of  frequent hospitalization since he had cardiac arrest/MI. Tested positive for COVID, was hyoxic. Started on IV abx, steroids, Vit C, vibramycin, zinc.  Had AKI on CKD IV. Renal status worsened. Had poor prognosis. Family and patient wanted HD. quinton was placed amd HD initiated. Had metabolic encephalopathy, CT head was neg. Likely due to pneumonia and AKI. Patient is DNR; patient went in to asystole and passed away.  Pt up to NRB mask near end of hospitalization
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Confusional state, Death, Haemodialysis, Hallucination
Clinical narrative: presented to ER with weakness, increase confusion, hallucinations and decreased mobility. Patient has hx of  frequent hospitalization since he had cardiac arrest/MI. Tested positive for COVID, was hyoxic. Started on IV abx, steroids, Vit C, vibramycin, zinc.  Had AKI on CKD IV. Renal status worsened. Had poor prognosis. Family and patient wanted HD. quinton was placed amd HD initiated. Had metabolic encephalopathy, CT head was neg. Likely due to pneumonia and AKI. Patient is DNR; patient went in to asystole and passed away.  Pt up to NRB mask near end of hospitalization
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoxia, Metabolic encephalopathy, Mobility decreased, Pneumonia, Renal impairment
Clinical narrative: presented to ER with weakness, increase confusion, hallucinations and decreased mobility. Patient has hx of  frequent hospitalization since he had cardiac arrest/MI. Tested positive for COVID, was hyoxic. Started on IV abx, steroids, Vit C, vibramycin, zinc.  Had AKI on CKD IV. Renal status worsened. Had poor prognosis. Family and patient wanted HD. quinton was placed amd HD initiated. Had metabolic encephalopathy, CT head was neg. Likely due to pneumonia and AKI. Patient is DNR; patient went in to asystole and passed away.  Pt up to NRB mask near end of hospitalization
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: presented to ER with weakness, increase confusion, hallucinations and decreased mobility. Patient has hx of  frequent hospitalization since he had cardiac arrest/MI. Tested positive for COVID, was hyoxic. Started on IV abx, steroids, Vit C, vibramycin, zinc.  Had AKI on CKD IV. Renal status worsened. Had poor prognosis. Family and patient wanted HD. quinton was placed amd HD initiated. Had metabolic encephalopathy, CT head was neg. Likely due to pneumonia and AKI. Patient is DNR; patient went in to asystole and passed away.  Pt up to NRB mask near end of hospitalization
Age: 63.0
Sex: F
Vaccine: COVID19-2, FLU4
Symptoms: Arthralgia, Back pain, Pain in extremity
Clinical narrative: Moderate to Severe shoulder, arm and upper back pain
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory distress syndrome, Atypical pneumonia, C-reactive protein increased, COVID-19, COVID-19 pneumonia
Clinical narrative: Presented wtih cough, congestion, HA, mild hypoxia; CXR: Atypical PNA Dx: Acute respiratory distress due to COVID-19 virus secondary to COVID-19 pneumonia; Labs: D-dimere 0.79; CRP: 34.61;  Tx: oxygen, remdesivir, zinc, vitamin-C, dexamethasone 12/31 still desats with activity on room air; cont remdesivir and low O2; 1/2 normal sats with walking on room air; dc without O2
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Chest X-ray abnormal, Cough, Fibrin D dimer, Headache, Hypoxia
Clinical narrative: Presented wtih cough, congestion, HA, mild hypoxia; CXR: Atypical PNA Dx: Acute respiratory distress due to COVID-19 virus secondary to COVID-19 pneumonia; Labs: D-dimere 0.79; CRP: 34.61;  Tx: oxygen, remdesivir, zinc, vitamin-C, dexamethasone 12/31 still desats with activity on room air; cont remdesivir and low O2; 1/2 normal sats with walking on room air; dc without O2
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Oxygen saturation decreased, Respiratory tract congestion
Clinical narrative: Presented wtih cough, congestion, HA, mild hypoxia; CXR: Atypical PNA Dx: Acute respiratory distress due to COVID-19 virus secondary to COVID-19 pneumonia; Labs: D-dimere 0.79; CRP: 34.61;  Tx: oxygen, remdesivir, zinc, vitamin-C, dexamethasone 12/31 still desats with activity on room air; cont remdesivir and low O2; 1/2 normal sats with walking on room air; dc without O2
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Asthenia, COVID-19, COVID-19 pneumonia, Cardiac failure acute
Clinical narrative: presented to ED with progressive generalized weakness, dyspnea and anorexia over several weeks; +Covid-19 pneumonia and acute hypoxemic resp failure; treated with dexamethasone and remdesivir along with oxygen support and empiric abx (ceftriaxone+azithromycin). Abx were discontinued after 5 days. His condition improved with treatment but deteriorated after he completed 10-day course of dexamethasone. Hospitalization was complicated by acute metabolic encephalopathy and acute on chronic HFrEF. Respiratory failure with hypoxia and encephalopathy progressed quickly during the last 3 days of hospitalization which required sedation and BiPAP therapy. Family decided to transition to comfort care only on day 15. BiPAP was discontinued for comfort. Pt died on day 16.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Death, Decreased appetite, Dyspnoea, General physical health deterioration, Left ventricular failure
Clinical narrative: presented to ED with progressive generalized weakness, dyspnea and anorexia over several weeks; +Covid-19 pneumonia and acute hypoxemic resp failure; treated with dexamethasone and remdesivir along with oxygen support and empiric abx (ceftriaxone+azithromycin). Abx were discontinued after 5 days. His condition improved with treatment but deteriorated after he completed 10-day course of dexamethasone. Hospitalization was complicated by acute metabolic encephalopathy and acute on chronic HFrEF. Respiratory failure with hypoxia and encephalopathy progressed quickly during the last 3 days of hospitalization which required sedation and BiPAP therapy. Family decided to transition to comfort care only on day 15. BiPAP was discontinued for comfort. Pt died on day 16.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Metabolic encephalopathy, Positive airway pressure therapy, SARS-CoV-2 test positive
Clinical narrative: presented to ED with progressive generalized weakness, dyspnea and anorexia over several weeks; +Covid-19 pneumonia and acute hypoxemic resp failure; treated with dexamethasone and remdesivir along with oxygen support and empiric abx (ceftriaxone+azithromycin). Abx were discontinued after 5 days. His condition improved with treatment but deteriorated after he completed 10-day course of dexamethasone. Hospitalization was complicated by acute metabolic encephalopathy and acute on chronic HFrEF. Respiratory failure with hypoxia and encephalopathy progressed quickly during the last 3 days of hospitalization which required sedation and BiPAP therapy. Family decided to transition to comfort care only on day 15. BiPAP was discontinued for comfort. Pt died on day 16.
Age: 84.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Hallucinations, mixed, SARS-CoV-2 test positive, Urinary tract infection
Clinical narrative: Presented with worsening visual/auditory hallucinations and weakness; Dx: recurrent UTI and +covid infection;  Recieved antibiotics for UTI and low dose decadron for covid; on room air at discharge;
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Aspiration pleural cavity, Atelectasis, C-reactive protein, Chest X-ray abnormal, Chest pain
Clinical narrative: Presented with CP/SOB, hypoxia; Labs: D-dimer 4.88, CRP 6; Ferritin 914.6; CXR: Pulm vascular congestion, pleural effusions, base atelectasis/infiltrate; Tx: Zithromax, Maxipime, Decadron, remdesivir, Vit C, Vit D3, Solu-medrol, singulair, Zinc; Pt with minimal supplemental O2 need; 2-3 LPM via NC; back to room air by dc;   Attempted thoracentesis on 12/28; minimal fluid obtained
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Fibrin D dimer, Hypoxia, Lung infiltration, Pleural effusion
Clinical narrative: Presented with CP/SOB, hypoxia; Labs: D-dimer 4.88, CRP 6; Ferritin 914.6; CXR: Pulm vascular congestion, pleural effusions, base atelectasis/infiltrate; Tx: Zithromax, Maxipime, Decadron, remdesivir, Vit C, Vit D3, Solu-medrol, singulair, Zinc; Pt with minimal supplemental O2 need; 2-3 LPM via NC; back to room air by dc;   Attempted thoracentesis on 12/28; minimal fluid obtained
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Pulmonary congestion, Serum ferritin increased
Clinical narrative: Presented with CP/SOB, hypoxia; Labs: D-dimer 4.88, CRP 6; Ferritin 914.6; CXR: Pulm vascular congestion, pleural effusions, base atelectasis/infiltrate; Tx: Zithromax, Maxipime, Decadron, remdesivir, Vit C, Vit D3, Solu-medrol, singulair, Zinc; Pt with minimal supplemental O2 need; 2-3 LPM via NC; back to room air by dc;   Attempted thoracentesis on 12/28; minimal fluid obtained
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Anticoagulant therapy, Atrial fibrillation, Blood creatinine, COVID-19
Clinical narrative: Presented with cough/sob. Dx + Covid 4 days PTA; Found to have COVID-19 pneumonia and acute hypoxic respiratory failure.  Coid symptoms x10 days; CXR: multifocal PNA; His condition worsened and he was requiring high-flow nasal cannula.  Started on IV antibiotics, remdesivir (1/26), baricitinib(2/1) , anticoagulation, Vit C, Vit D3, Zinc.  He had atrial fibrillation-Started on full-dose anticoagulation.  His condition worsened, intubated (2/7) and transferred to medical ICU.  Patient and family was not interested in aggressive measures however they agreed for intubation for a brief period of time.  After intubation his condition continued to get worsen.  He had respiratory acidosis and worsening renal function. Creatinine worsened to 5.54 family refused dialysis. Family decided on  scomfort care measures; pt expired
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Chest X-ray abnormal, Cough, Death, Dyspnoea
Clinical narrative: Presented with cough/sob. Dx + Covid 4 days PTA; Found to have COVID-19 pneumonia and acute hypoxic respiratory failure.  Coid symptoms x10 days; CXR: multifocal PNA; His condition worsened and he was requiring high-flow nasal cannula.  Started on IV antibiotics, remdesivir (1/26), baricitinib(2/1) , anticoagulation, Vit C, Vit D3, Zinc.  He had atrial fibrillation-Started on full-dose anticoagulation.  His condition worsened, intubated (2/7) and transferred to medical ICU.  Patient and family was not interested in aggressive measures however they agreed for intubation for a brief period of time.  After intubation his condition continued to get worsen.  He had respiratory acidosis and worsening renal function. Creatinine worsened to 5.54 family refused dialysis. Family decided on  scomfort care measures; pt expired
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Endotracheal intubation, General physical health deterioration, Intensive care, Malaise, Renal impairment
Clinical narrative: Presented with cough/sob. Dx + Covid 4 days PTA; Found to have COVID-19 pneumonia and acute hypoxic respiratory failure.  Coid symptoms x10 days; CXR: multifocal PNA; His condition worsened and he was requiring high-flow nasal cannula.  Started on IV antibiotics, remdesivir (1/26), baricitinib(2/1) , anticoagulation, Vit C, Vit D3, Zinc.  He had atrial fibrillation-Started on full-dose anticoagulation.  His condition worsened, intubated (2/7) and transferred to medical ICU.  Patient and family was not interested in aggressive measures however they agreed for intubation for a brief period of time.  After intubation his condition continued to get worsen.  He had respiratory acidosis and worsening renal function. Creatinine worsened to 5.54 family refused dialysis. Family decided on  scomfort care measures; pt expired
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Respiratory acidosis, SARS-CoV-2 test positive
Clinical narrative: Presented with cough/sob. Dx + Covid 4 days PTA; Found to have COVID-19 pneumonia and acute hypoxic respiratory failure.  Coid symptoms x10 days; CXR: multifocal PNA; His condition worsened and he was requiring high-flow nasal cannula.  Started on IV antibiotics, remdesivir (1/26), baricitinib(2/1) , anticoagulation, Vit C, Vit D3, Zinc.  He had atrial fibrillation-Started on full-dose anticoagulation.  His condition worsened, intubated (2/7) and transferred to medical ICU.  Patient and family was not interested in aggressive measures however they agreed for intubation for a brief period of time.  After intubation his condition continued to get worsen.  He had respiratory acidosis and worsening renal function. Creatinine worsened to 5.54 family refused dialysis. Family decided on  scomfort care measures; pt expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Anticoagulant therapy, Asthenia, COVID-19, Chronic kidney disease
Clinical narrative: Presented with SOB/weakness; Date of onset of symptoms 12/24.  Tested positive on 12/27.   Tx: completed 5 days remdesivir, IV Solu-Medrol; Zithromax, Lovenox, merrem, singulair, zinc; AKI on CKD 3:  Suspect either due to over-diuresis or COVID-19 infection.  Has improved back to baseline. Minimal supplemental O2 needed; did require bipap briefly initially; down to baseline of 4 LPM o2 at time of d/c
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Polyuria, Positive airway pressure therapy, SARS-CoV-2 test positive
Clinical narrative: Presented with SOB/weakness; Date of onset of symptoms 12/24.  Tested positive on 12/27.   Tx: completed 5 days remdesivir, IV Solu-Medrol; Zithromax, Lovenox, merrem, singulair, zinc; AKI on CKD 3:  Suspect either due to over-diuresis or COVID-19 infection.  Has improved back to baseline. Minimal supplemental O2 needed; did require bipap briefly initially; down to baseline of 4 LPM o2 at time of d/c
Age: 32.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, Product storage error
Clinical narrative: Patient received COVID 19 vaccine that had been stored beyond the Beyond Use Date.
Age: 36.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient received COVID 19 vaccine that had been stored beyond the Beyond Use Date.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Anticoagulant therapy, COVID-19, Chest X-ray normal, Cough, Fibrin D dimer increased
Clinical narrative: Pt presented with syncope d/t coughing; CXR: clear; dx: Covid infection Tx: solumedrol, Vit C, Vit D3, Zinc, Singulair, lovenox; no criteria met for remdesivir or tocilizumab; minimal O2 support with 1 LPM NC; back to room air baseline by d/c; elequis continued at dc due to elevated d-dimer
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Syncope
Clinical narrative: Pt presented with syncope d/t coughing; CXR: clear; dx: Covid infection Tx: solumedrol, Vit C, Vit D3, Zinc, Singulair, lovenox; no criteria met for remdesivir or tocilizumab; minimal O2 support with 1 LPM NC; back to room air baseline by d/c; elequis continued at dc due to elevated d-dimer
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Asthenia, C-reactive protein normal, COVID-19, COVID-19 pneumonia
Clinical narrative: Presented with weakness, SOB, cough, dec appetite; CXR:  Patchy bilat airspace opacification, concerning for atypical PNA; dx Type II NSTEMI d/t Covid; Covid PNA;  Labs: D-dimer 0.84, CRP 0.4; Ferritin 1458; remained on baseline 3 LPM NC; Meds: Singulair, Zinc; feeling much better from COVID-19 infection no evidence of significant pneumonia however patient is having a productive cough and therefore will treat him with a short course of steroid and antibiotic due to his underlying interstitial lung disease.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Chest X-ray abnormal, Cough, Decreased appetite, Dyspnoea, Fibrin D dimer
Clinical narrative: Presented with weakness, SOB, cough, dec appetite; CXR:  Patchy bilat airspace opacification, concerning for atypical PNA; dx Type II NSTEMI d/t Covid; Covid PNA;  Labs: D-dimer 0.84, CRP 0.4; Ferritin 1458; remained on baseline 3 LPM NC; Meds: Singulair, Zinc; feeling much better from COVID-19 infection no evidence of significant pneumonia however patient is having a productive cough and therefore will treat him with a short course of steroid and antibiotic due to his underlying interstitial lung disease.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Interstitial lung disease, Lung opacity, Productive cough, Serum ferritin increased
Clinical narrative: Presented with weakness, SOB, cough, dec appetite; CXR:  Patchy bilat airspace opacification, concerning for atypical PNA; dx Type II NSTEMI d/t Covid; Covid PNA;  Labs: D-dimer 0.84, CRP 0.4; Ferritin 1458; remained on baseline 3 LPM NC; Meds: Singulair, Zinc; feeling much better from COVID-19 infection no evidence of significant pneumonia however patient is having a productive cough and therefore will treat him with a short course of steroid and antibiotic due to his underlying interstitial lung disease.
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, C-reactive protein normal, COVID-19 pneumonia, Chest X-ray abnormal, Dyspnoea
Clinical narrative: Presented with SOB, gen weakness; CXR: Diffuse Reticular infiltrates; Labs: D-dimer-  0.83; CRP 0.59; Ferritin: 191.9; Dx: Covid PNA; Meds: Zithromax, Maxipime, Solumedrol, Rocephin, Vit D3, Decadron, Lovenox, Singulair, Zinc  (did not receive actemra as drug was not available)
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Fibrin D dimer, Lung infiltration, Serum ferritin normal
Clinical narrative: Presented with SOB, gen weakness; CXR: Diffuse Reticular infiltrates; Labs: D-dimer-  0.83; CRP 0.59; Ferritin: 191.9; Dx: Covid PNA; Meds: Zithromax, Maxipime, Solumedrol, Rocephin, Vit D3, Decadron, Lovenox, Singulair, Zinc  (did not receive actemra as drug was not available)
Age: 62.0
Sex: F
Vaccine: FLU4, VARZOS
Symptoms: Chills, Pain, Pyrexia
Clinical narrative: Fever, chills, aches
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Hypotension, SARS-CoV-2 test positive
Clinical narrative: Presented with hypotension; diagnosed with COVID-19 in January and still tested positive. Patient was placed on oxygen, restarted back on steroids but he was able to be quickly weaned off to room air. Meds: Decadron, Singulair,  zinc
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Anticoagulant therapy, COVID-19, Chest X-ray abnormal, Dyspnoea, Hypoxia
Clinical narrative: Presented with SOB, hypoxia, recent + covid; CXR: Left lung PNA and LLL empyema;  Started on steroids and antibiotics for PNA; 2/21 L VATS for empyema; developed mild ileus post op, recovered by d/c; Meds: Rocephin, Vit c, Vit D3, Zithromax, Decadron, Lovenox, Zinc; Initially on minimal supplemental O2 @ 4 LPM NC; weaned to room air by d/c
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Infectious pleural effusion, Pneumonia, Postoperative ileus, SARS-CoV-2 test positive, Thoracic operation
Clinical narrative: Presented with SOB, hypoxia, recent + covid; CXR: Left lung PNA and LLL empyema;  Started on steroids and antibiotics for PNA; 2/21 L VATS for empyema; developed mild ileus post op, recovered by d/c; Meds: Rocephin, Vit c, Vit D3, Zithromax, Decadron, Lovenox, Zinc; Initially on minimal supplemental O2 @ 4 LPM NC; weaned to room air by d/c
Age: 16.0
Sex: M
Vaccine: HIBV
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Patient was given the wrong vaccine, Meningococcal was ordered and HIB (meningococcal protein conjugate) was given
Age: 50.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient received COVID 19 vaccine that had been stored beyond the Beyond Use Date.
Age: 77.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient received COVID 19 vaccine that had been stored beyond the Beyond Use Date.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Anticoagulant therapy, Asthenia, C-reactive protein increased, COVID-19 pneumonia, Chest X-ray abnormal
Clinical narrative: Presented with weakness, SOB x4 days, hypoxic; DX Covid PNA, DVT, PE; CXR: Left basilar patchy opacity suspicious for PNA; Labs: D dimer: 9.52; CRP 27.91; Ferritin 2388; Meds: Maxipime, Lovenox, Decadron, Rocephin, Lovenox, Zinc, ; supplemental O2 @ 3-4 LPM NC; weaned to room air by d/c; no remdesivir due to renal concerns; Did not meet criteria for actemra
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Deep vein thrombosis, Dyspnoea, Fibrin D dimer, Hypoxia, Lung opacity
Clinical narrative: Presented with weakness, SOB x4 days, hypoxic; DX Covid PNA, DVT, PE; CXR: Left basilar patchy opacity suspicious for PNA; Labs: D dimer: 9.52; CRP 27.91; Ferritin 2388; Meds: Maxipime, Lovenox, Decadron, Rocephin, Lovenox, Zinc, ; supplemental O2 @ 3-4 LPM NC; weaned to room air by d/c; no remdesivir due to renal concerns; Did not meet criteria for actemra
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Pneumonia, Serum ferritin increased
Clinical narrative: Presented with weakness, SOB x4 days, hypoxic; DX Covid PNA, DVT, PE; CXR: Left basilar patchy opacity suspicious for PNA; Labs: D dimer: 9.52; CRP 27.91; Ferritin 2388; Meds: Maxipime, Lovenox, Decadron, Rocephin, Lovenox, Zinc, ; supplemental O2 @ 3-4 LPM NC; weaned to room air by d/c; no remdesivir due to renal concerns; Did not meet criteria for actemra
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Angiogram pulmonary normal, Anticoagulant therapy, C-reactive protein, COVID-19, COVID-19 pneumonia
Clinical narrative: Presented with worsening SOB/cough, hypoxia; initially dx + Covid 1/10 and improved, now worse; CXR: Bilat PNA; Dx Covid PNA; Labs: D-dimer 1.0, CRP 8.17; Ferritin 355; Tx:  continued on IV steroids and Lovenox, zinc; oxygen requirements increased and placed on Airvo on 1/25.  Received a dose of Actrema (1/25).  Pulmonary consult requested from Dr. in view of persistent high oxygen requirements.  CT angio showed no signs of any pulmonary embolism.  Patient received 2nd dose of Bactrim on 02/05/22.  Patient is a DNR and as long discussed with patient and she does not want intubation.  Symptoms got worse and remained on BiPAP continuously and unable to oxygen at on Airvo and non-rebreather.  Patient and family d
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Chest X-ray abnormal, Cough, Dyspnoea, Fibrin D dimer, Hypoxia
Clinical narrative: Presented with worsening SOB/cough, hypoxia; initially dx + Covid 1/10 and improved, now worse; CXR: Bilat PNA; Dx Covid PNA; Labs: D-dimer 1.0, CRP 8.17; Ferritin 355; Tx:  continued on IV steroids and Lovenox, zinc; oxygen requirements increased and placed on Airvo on 1/25.  Received a dose of Actrema (1/25).  Pulmonary consult requested from Dr. in view of persistent high oxygen requirements.  CT angio showed no signs of any pulmonary embolism.  Patient received 2nd dose of Bactrim on 02/05/22.  Patient is a DNR and as long discussed with patient and she does not want intubation.  Symptoms got worse and remained on BiPAP continuously and unable to oxygen at on Airvo and non-rebreather.  Patient and family d
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Pneumonia, Positive airway pressure therapy, SARS-CoV-2 test positive, Serum ferritin increased
Clinical narrative: Presented with worsening SOB/cough, hypoxia; initially dx + Covid 1/10 and improved, now worse; CXR: Bilat PNA; Dx Covid PNA; Labs: D-dimer 1.0, CRP 8.17; Ferritin 355; Tx:  continued on IV steroids and Lovenox, zinc; oxygen requirements increased and placed on Airvo on 1/25.  Received a dose of Actrema (1/25).  Pulmonary consult requested from Dr. in view of persistent high oxygen requirements.  CT angio showed no signs of any pulmonary embolism.  Patient received 2nd dose of Bactrim on 02/05/22.  Patient is a DNR and as long discussed with patient and she does not want intubation.  Symptoms got worse and remained on BiPAP continuously and unable to oxygen at on Airvo and non-rebreather.  Patient and family d
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Cough, Dyspnoea, Pneumonia, Pyrexia
Clinical narrative: h/o COVID (12/2020) c/b post-COVID long hauler syndrome follows with Dr. who p/w fevers, dyspnea & cough being admitted for sepsis & acute hypoxic respiratory failure 2/2 multifocal pneumonia. tx: Maxipime, rocephin, singulair; maintained on Ceftriaxone and Azithromycin during hospitalization as per ID. O2 was weaned and walking oximetry test was 94% on room air.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Sepsis
Clinical narrative: h/o COVID (12/2020) c/b post-COVID long hauler syndrome follows with Dr. who p/w fevers, dyspnea & cough being admitted for sepsis & acute hypoxic respiratory failure 2/2 multifocal pneumonia. tx: Maxipime, rocephin, singulair; maintained on Ceftriaxone and Azithromycin during hospitalization as per ID. O2 was weaned and walking oximetry test was 94% on room air.
Age: 60.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient received COVID 19 vaccine that had been stored beyond the Beyond Use Date.
Age: 10.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient received COVID 19 vaccine that had been stored beyond the Beyond Use Date.
Age: 12.0
Sex: F
Vaccine: HPV9
Symptoms: Needle issue
Clinical narrative: During administration, unable to completely push entire contents of syringe and dose.  Adminsitering MA had to withdraw the needle and obtain a new sterile needle.  The remainder of the dose was adminstered in the same arm 1 inch apart.
Age: 11.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient received COVID 19 vaccine that had been stored beyond the Beyond Use Date.
Age: 72.0
Sex: F
Vaccine: ADEN_4_7
Symptoms: Erythema, Peripheral swelling, Skin warm
Clinical narrative: Arm red, swollen, hot
Age: 68.0
Sex: F
Vaccine: FLUA4
Symptoms: Dyspnoea, Hypoaesthesia oral, Pharyngeal hypoaesthesia, Swollen tongue, Throat irritation
Clinical narrative: I had numbness in my lips, tongue was numb and felt swollen, throat felt itchy. Had some shortness of breath. I got home took. Benadryl 50 mg. I was at the ER for about4 hours. I left the emergency room it was busy and I felt better the numbness in my throat,tongue, and lips had gone . I took an additional dose of Benadryl at bedtime.
Age: 6.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient received COVID 19 vaccine that had been stored beyond the Beyond Use Date.
Age: 45.0
Sex: F
Vaccine: HPV9
Symptoms: Syncope
Clinical narrative: I got up in the middle of the night and fainted. I have been on the medications I listed for years and take them every night and this has never happened to me aside from the night after I received the HPV vaccine.
Age: 10.0
Sex: F
Vaccine: MNQ
Symptoms: Inappropriate schedule of product administration
Clinical narrative: patient was given a menquadfi vaccine before the actually due date by accident no symptoms or anything occurred.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site rash, Rash, Rash erythematous, Rash papular, Rash pruritic
Clinical narrative: Rash near injection site, roughly 10 x 9 cm. Rash was red, raised, painful, itch.
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Pyrexia, Rhinorrhoea, Vomiting
Clinical narrative: fever following day, clingy, vomited x1 day after vaccination, now with runny nose suspicious for URI
Age: 41.0
Sex: F
Vaccine: FLU4
Symptoms: Cough, Feeling hot, Foreign body in throat, Throat clearing, Throat irritation
Clinical narrative: She noticed clearing throat a lot, cough, throat hot and had a tickle in it. "something felt stuck in my throat and couldn't dislodge with throat clearing."
Age: 76.0
Sex: F
Vaccine: RSV
Symptoms: Blood test normal, Computerised tomogram normal, Diarrhoea, Dizziness, Fall
Clinical narrative: Patient felt lightheaded and dizzy during the day on 9/27/23. She fainted around 5 pm on 9/27/23 and was taken by ambulance to ER..
Age: 76.0
Sex: F
Vaccine: RSV
Symptoms: Syncope, Urine analysis normal
Clinical narrative: Patient felt lightheaded and dizzy during the day on 9/27/23. She fainted around 5 pm on 9/27/23 and was taken by ambulance to ER..
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Asthenia, Burning sensation, Chills, Dizziness, Erythema
Clinical narrative: In first 5 min after shot felt dizzy, Remained seated for 15 min and dizziness ended. Felt slightly disoriented for one hour but able to function. About 90 min after shot, vision was blurred and began feeling the top of head burning.  Inspection of head showed no redness but burning equal to second degree burn continued for 24 hrs and treated it with cold wet cloths which eased pain.  Two hours after injection, vision improved but became hyperactive and did housework for 3 hours. Headache and fatigue began and pain in right arm shooting down to fingers. Injection shot became hot and swollen and continued.   Sore throat, muscle aches, nausea, weakness, fever, chills began 6hrs after injection and lasted  12hrs. Treated with Zofran and Tylenol. Tylenol wasn?t effective and switched to Tramadol with Tylenol was effective.
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Fatigue, Headache, Injection site swelling, Injection site warmth, Myalgia
Clinical narrative: In first 5 min after shot felt dizzy, Remained seated for 15 min and dizziness ended. Felt slightly disoriented for one hour but able to function. About 90 min after shot, vision was blurred and began feeling the top of head burning.  Inspection of head showed no redness but burning equal to second degree burn continued for 24 hrs and treated it with cold wet cloths which eased pain.  Two hours after injection, vision improved but became hyperactive and did housework for 3 hours. Headache and fatigue began and pain in right arm shooting down to fingers. Injection shot became hot and swollen and continued.   Sore throat, muscle aches, nausea, weakness, fever, chills began 6hrs after injection and lasted  12hrs. Treated with Zofran and Tylenol. Tylenol wasn?t effective and switched to Tramadol with Tylenol was effective.
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Nausea, Oropharyngeal pain, Pain, Pain in extremity, Psychomotor hyperactivity
Clinical narrative: In first 5 min after shot felt dizzy, Remained seated for 15 min and dizziness ended. Felt slightly disoriented for one hour but able to function. About 90 min after shot, vision was blurred and began feeling the top of head burning.  Inspection of head showed no redness but burning equal to second degree burn continued for 24 hrs and treated it with cold wet cloths which eased pain.  Two hours after injection, vision improved but became hyperactive and did housework for 3 hours. Headache and fatigue began and pain in right arm shooting down to fingers. Injection shot became hot and swollen and continued.   Sore throat, muscle aches, nausea, weakness, fever, chills began 6hrs after injection and lasted  12hrs. Treated with Zofran and Tylenol. Tylenol wasn?t effective and switched to Tramadol with Tylenol was effective.
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Pyrexia, Vision blurred
Clinical narrative: In first 5 min after shot felt dizzy, Remained seated for 15 min and dizziness ended. Felt slightly disoriented for one hour but able to function. About 90 min after shot, vision was blurred and began feeling the top of head burning.  Inspection of head showed no redness but burning equal to second degree burn continued for 24 hrs and treated it with cold wet cloths which eased pain.  Two hours after injection, vision improved but became hyperactive and did housework for 3 hours. Headache and fatigue began and pain in right arm shooting down to fingers. Injection shot became hot and swollen and continued.   Sore throat, muscle aches, nausea, weakness, fever, chills began 6hrs after injection and lasted  12hrs. Treated with Zofran and Tylenol. Tylenol wasn?t effective and switched to Tramadol with Tylenol was effective.
Age: 65.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site rash, Injection site swelling, Pruritus
Clinical narrative: PATIENT REPORTS RASH AND SWOLLEN AT SITE ON INJECTION AND ITCHY.
Age: 67.0
Sex: F
Vaccine: COVID19-2, FLU4
Symptoms: Arthralgia, Blood test, Body temperature increased, Computerised tomogram, Magnetic resonance imaging
Clinical narrative: Transient Global Amnesia -lasted approximately 6 hours .  Woke up that morning with a migraine and took one prescribed migraine pill.  I ran a temperature the evening of Sept 20 and had painful joints until 11:00 am on Sept 21
Age: 67.0
Sex: F
Vaccine: COVID19-2, FLU4
Symptoms: Migraine, Transient global amnesia
Clinical narrative: Transient Global Amnesia -lasted approximately 6 hours .  Woke up that morning with a migraine and took one prescribed migraine pill.  I ran a temperature the evening of Sept 20 and had painful joints until 11:00 am on Sept 21